All Company Risk articles – Page 5
-
AnalysisRisk culture lacking, survey reveals
A “significant task” ahead to embed risk culture, says the IRM’s deputy head
-
InterviewsLloyd’s and Bermuda converging
A report finds the underwriting differences between London and Bermuda are thinning
-
-
InterviewsWorth the effort
Solvency II will benefit the whole insurance industry, writes Chris Lajtha in response to Carl Leeman’s blog
-
AnalysisA new approach to regulation
A summary of the UK government’s recommendations for regulatory change
-
AnalysisCan Dodd-Frank stop another crisis?
The sweeping overhaul of US financial regulation fails to address the main causes of the financial crisis, says Matthew Kerfoot
-
AnalysisTop 5 mega earthquake hotspots
They are the Caribbean, North America, Chile, Indonesia and Japan
-
-
Online onlyReport reveals bribe trends in Brazil
Officials account for most demands and cash is the preferred bribe
-
InterviewsCoke sued for cutting strikers health care
500 striking workers in Washington launched a class action after their health plans were cut
-
-
InterviewsAstraZeneca settles with drug users
The company paid £125m to settle about two thirds of seroquel personal injury claims in the US
-
GraphicsInfographic: Global risks spectrum
36 economic, environmental, geopolitical, societal and technological risks mapped
-
InterviewsMore trouble than its worth
Solvency II will severely restrict the commercial insurance market. It’s time Europe listened to the concerns of risk managers, blogs Carl Leeman
-
Interviews
Lloyds bank appoints people risk director
Sandra Quinn joins from the financial regulator
-
Online onlyVideographic: Who owns America’s debt?
A dynamic perspective of the major foreign holders of US government debt
-
GraphicsInfographic: Tracking the history of the FTSE100
Visual graphic shows how the value and composition of the index has changed over 26 years
-
-
-
FeaturesWinning treatment
Launching a series of fi rst-hand accounts of practical risk management, Mike Florence, who led AstraZeneca’s programme, explains how the team’s strategy has breathed new life into its respiratory and infl ammatory efforts
